MDGL

Madrigal Pharmaceuticals, Inc. Common Stock

495.04

USD

MDGL Earnings Reports

Positive Surprise Ratio

MDGL beat 22 of 40 last estimates.

55%

Next Report

Date of Next Report

Feb 24, 2026

Estimate for Q4 25 (Revenue/ EPS)

$316.47M

-$0.77

Implied change from Q3 25 (Revenue/ EPS)

+10.17%

-84.48%

Implied change from Q4 24 (Revenue/ EPS)

+206.30%

-71.59%

Madrigal Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 04, 2025, MDGL reported earnings of -4.96 USD per share (EPS) for Q3 25, missing the estimate of -2.12 USD, resulting in a -133.61% surprise. Revenue reached 287.27 million, compared to an expected 252.25 million, with a 13.88% difference. The market reacted with a +7.83% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 18 analysts forecast an EPS of -0.77 USD, with revenue projected to reach 316.47 million USD, implying an decrease of -84.48% EPS, and increase of 10.17% in Revenue from the last quarter.

FAQ

What were Madrigal Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Madrigal Pharmaceuticals, Inc. Common Stock reported EPS of -$4.96, missing estimates by -133.61%, and revenue of $287.27M, 13.88% above expectations.

How did the market react to Madrigal Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 7.83%, changed from $412.35 before the earnings release to $444.64 the day after.

When is Madrigal Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 24, 2026.

What are the forecasts for Madrigal Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on 18 analysts, Madrigal Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.77 and revenue of $316.47M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.